Archive for the ‘Advanced Viral Research Corp. ADVR’ Category

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 31% Intraday and Up as Much as 123% Since Last Tuesday

Wednesday, April 30th, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 31% Intraday and Up as Much as 123% Since Last Tuesday

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up 20% Intraday and Up as Much as 84% Since Last Tuesday

Tuesday, April 29th, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up 20% Intraday and Up as Much as 84% Since Last Tuesday

Last Tuesday’s Close: $0.013

Yesterday’s Close: $0.02

Today’s Intraday High: $0.24

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up More than 84% Intraday

Monday, April 14th, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up More than 84% Intraday

Friday’s Close: $0.013

Today’s Intraday High: $0.024

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up as Much as 66% Since Monday

Wednesday, April 2nd, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up as Much as 66% Since Monday

Monday’s Close: $0.009

Today’s Intraday High: $0.015

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up 40% this Morning and Up 50% Since Thursday

Monday, March 3rd, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up 40% this Morning and Up 50% Since Thursday

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 16% Friday Morning

Friday, February 29th, 2008

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 16% Friday Morning

Beacon Equity Featured Company: Advanced Viral Research Corp. (ADVR.OB)

Wednesday, December 26th, 2007

Advanced Viral Research Corp. (ADVR.OB) is a biopharmaceutical company focused on improving the lives of patients by researching, developing and marketing innovative therapies for a range of serious disorders and diseases.

The company is primarily committed to bringing its flagship product, AVR118, to patients. AVR118 appears to have the potential to stimulate the pro-inflammatory response needed to fight viral infections, including HIV, as well as reduce aberrant autoimmune-type inflammatory responses.

In January of 2005, Advanced Viral Research Corp. reported the results from its Phase I/II clinical trial of AVR118 in patients with AIDS. The results demonstrated that the product has continued to show potential to offer unique benefits, a favorable safety profile, and no apparent drug-related undesirable effects.

Let us hear your thoughts: Advanced Viral Research Corp. Message Board

StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 18% in Early Trading

Wednesday, September 26th, 2007
StockGuru Trade Alert: Guru Profile Advanced Viral Research (ADVR) Up Over 18% in Early Trading

Disclosure: Pentony Enterprises LLC was compensated 158,000 free trading shares from a non controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises no longer holds shares.

StockGuru News: Advanced Viral Research (ADVR) is Granted US Patent for Rheumatoid Arthritis

Monday, July 17th, 2006
Advanced Viral Research (ADVR) is Granted US Patent for Rheumatoid Arthritis

Advanced Viral Research Corporation
(OTCBB: ADVR)

YONKERS, N.Y.–(BUSINESS WIRE)–July 17, 2006–Advanced Viral Research Corp. (OTC Bulletin Board: ADVR – News) a bio-pharmaceutical company, announced today that effective June 27, 2006, the company has received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation. Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens. This illness affects about one percent of the world’s population.

“We are excited that the US Patent Office has granted us with this important patent,” says Stephen M. Elliston, CEO and President of Advanced Viral Research. “With such a large population affected by rheumatoid arthritis, the commercial prospects for AVR118 may potentially be expanded to include patients suffering from this debilitating disease. This also comes at a time when the treatment options for RA have been limited significantly by the withdrawal of COX II inhibitors from the market.”

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients’ lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR’s lead product, AVR118 (formerly known as Product R), represents a complex mixture of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases that possesses, among other things, immunomodulatory activity. We believe it may be employed in the treatment of diseases and conditions such as: Various conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS), cancer, human immunodeficiency virus, or HIV, including AIDS as a combination therapy; type 2 diabetes; human papilloma virus, or HPV; and rheumatoid arthritis. ADVR is in clinical trials for treatment of cachexia (body wasting) in patients with AIDS.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described From time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable Agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future Events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.

Contact:

Equity Relations, Inc.
Richard Brown, 617-314-7379
staff@equityrelations.com

Source: Advanced Viral Research Corp.

View the StockGuru Profile for Advanced Viral Research Corporation:

http://www.stockguru.com/profiles/advr/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated 158,000 shares from a non controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.